import { EducationalContent } from '../../types';

export const vascularDisease: EducationalContent = {
  id: 'vasculardisease',
  type: 'concept',
  name: 'Vascular Disease Overview',
  nameEs: 'Enfermedad Vascular',
  levels: {
    1: {
      level: 1,
      summary: 'Vascular disease encompasses conditions affecting the blood vessels throughout the body, including arteries, veins, and lymphatic vessels, with atherosclerosis being the most common underlying cause of arterial disease.',
      explanation: 'The vascular system is the body\'s network of blood vessels that carries blood to and from every organ. Arteries carry oxygen-rich blood from the heart to the body, veins return oxygen-poor blood back to the heart, and lymphatic vessels help drain fluid from tissues. Vascular disease refers to any abnormal condition of these vessels. The most common type is arterial disease caused by atherosclerosis, where fatty deposits (plaques) build up inside artery walls over many years, gradually narrowing them and reducing blood flow. This same process can affect arteries anywhere in the body: in the heart (coronary artery disease leading to heart attacks), in the brain (carotid artery disease leading to strokes), in the legs (peripheral artery disease leading to leg pain and amputation), in the kidneys (renal artery disease), and in the aorta (aneurysms and dissections). Risk factors for atherosclerotic vascular disease include smoking, high blood pressure, high cholesterol, diabetes, obesity, physical inactivity, and family history. Other types of vascular disease include aneurysms (weakening and bulging of artery walls), venous disease (blood clots in veins and varicose veins), and vasculitis (inflammation of blood vessel walls). Because atherosclerosis is a systemic process, a patient with disease in one vascular bed is at high risk for disease in others. For example, a patient with peripheral artery disease has a significantly elevated risk of heart attack and stroke. Treatment of vascular disease focuses on managing risk factors (smoking cessation, blood pressure control, cholesterol reduction, diabetes management), medications (blood thinners, cholesterol-lowering drugs), and procedures to restore blood flow when vessels become severely narrowed or blocked.',
      keyTerms: [
        { term: 'Vascular disease', definition: 'A broad category of conditions affecting blood vessels including arteries, veins, and lymphatic vessels' },
        { term: 'Atherosclerosis', definition: 'A chronic disease where fatty plaques build up inside artery walls, narrowing them and reducing blood flow to organs' },
        { term: 'Aneurysm', definition: 'An abnormal bulging or widening of a blood vessel wall due to weakness, with risk of rupture' },
        { term: 'Carotid artery disease', definition: 'Narrowing of the carotid arteries in the neck that supply the brain, increasing the risk of stroke' },
        { term: 'Venous disease', definition: 'Conditions affecting the veins, including deep vein thrombosis (blood clots) and chronic venous insufficiency' }
      ],
      clinicalNotes: 'Vascular disease is the leading cause of death and disability worldwide. The key clinical principle is that atherosclerosis is systemic: when disease is found in one vascular territory, other territories should be assessed. Risk factor modification, particularly smoking cessation, is the single most impactful intervention across all forms of vascular disease.'
    },
    2: {
      level: 2,
      summary: 'Vascular disease includes arterial conditions (atherosclerotic occlusive disease, aneurysmal disease, vasospastic disorders), venous conditions (DVT, PE, CVI), and lymphatic disease. Systemic atherosclerosis risk assessment and polyvascular disease management are central to vascular medicine.',
      explanation: 'Vascular disease is organized into arterial, venous, and lymphatic categories. Arterial diseases include: (1) Atherosclerotic occlusive disease: coronary artery disease (CAD), carotid artery disease, peripheral artery disease (PAD), renal artery stenosis, and mesenteric ischemia. (2) Aneurysmal disease: abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), popliteal artery aneurysm, and visceral artery aneurysms. (3) Acute aortic syndromes: aortic dissection, intramural hematoma, and penetrating atherosclerotic ulcer. (4) Non-atherosclerotic arterial disease: fibromuscular dysplasia (FMD), Takayasu arteritis, giant cell arteritis, Buerger disease (thromboangiitis obliterans), and Raynaud phenomenon. Venous diseases include: (1) Venous thromboembolism (VTE): deep vein thrombosis (DVT) and pulmonary embolism (PE). (2) Chronic venous disease: varicose veins, chronic venous insufficiency (CVI) with skin changes and ulceration. (3) Superficial thrombophlebitis. Lymphatic diseases include lymphedema (primary genetic or secondary from surgery/radiation/infection). The concept of polyvascular disease is clinically important: patients with disease in multiple vascular beds (e.g., PAD plus CAD, or carotid disease plus PAD) have significantly worse outcomes than those with disease in a single territory. The REACH registry showed that patients with disease in 3 vascular beds had a 26% rate of cardiovascular death, MI, or stroke at 1 year, compared to 13% for single-territory disease. Vascular risk assessment uses tools like the ASCVD risk calculator, ankle-brachial index (screening for PAD), carotid intima-media thickness, coronary artery calcium scoring, and assessment for subclinical atherosclerosis. Medical management principles apply across all atherosclerotic vascular disease: antiplatelet therapy (aspirin, clopidogrel, or dual pathway with low-dose rivaroxaban), high-intensity statin therapy, blood pressure control, glycemic management in diabetes, and lifestyle modifications (smoking cessation, regular exercise, Mediterranean diet, and weight management). Carotid artery disease deserves specific mention: it is responsible for approximately 10-15% of ischemic strokes. Asymptomatic carotid stenosis greater than 70-80% and symptomatic stenosis greater than 50% are indications for carotid endarterectomy (CEA) or carotid artery stenting (CAS). CEA is generally preferred for most patients, while CAS may be favored for hostile neck anatomy, radiation-induced stenosis, or high surgical risk.',
      keyTerms: [
        { term: 'Polyvascular disease', definition: 'Atherosclerotic disease affecting multiple vascular territories simultaneously, carrying significantly worse prognosis than single-territory disease' },
        { term: 'Fibromuscular dysplasia', definition: 'A non-atherosclerotic arterial disease causing stenosis, aneurysm, or dissection, most commonly affecting renal and carotid arteries in young women' },
        { term: 'Venous thromboembolism', definition: 'A condition encompassing both deep vein thrombosis and pulmonary embolism, a major cause of vascular morbidity and mortality' },
        { term: 'Carotid endarterectomy', definition: 'Surgical removal of atherosclerotic plaque from the carotid artery to reduce stroke risk' },
        { term: 'REACH registry', definition: 'A large international registry demonstrating the high cardiovascular event rates in patients with polyvascular atherosclerotic disease' },
        { term: 'Chronic venous insufficiency', definition: 'A condition where leg veins cannot efficiently return blood to the heart, causing swelling, skin changes, and ulceration' }
      ],
      clinicalNotes: 'When a patient presents with disease in one vascular territory, perform a comprehensive vascular assessment: (1) PAD: check ABI bilaterally; (2) Carotid disease: auscultate for bruits, consider duplex ultrasound in high-risk patients; (3) AAA: one-time ultrasound screening per USPSTF recommendations; (4) CAD: assess symptoms, consider stress testing based on risk. This polyvascular perspective ensures that the most life-threatening disease (often CAD) is not overlooked while treating the presenting condition.'
    },
    3: {
      level: 3,
      summary: 'Advanced vascular disease management integrates multimodality vascular imaging, evidence-based revascularization strategies across territories, comprehensive antithrombotic regimens, and management of non-atherosclerotic conditions including fibromuscular dysplasia and vasculitis.',
      explanation: 'Comprehensive vascular imaging has evolved beyond duplex ultrasound. CTA provides rapid, high-resolution imaging of the entire arterial tree from arch to feet (CTA runoff study for PAD planning), the aorta (for aneurysm and dissection), and the carotid/cerebral circulation. MRA avoids radiation but is limited by metallic artifact and may overestimate stenosis severity. Intravascular ultrasound (IVUS) provides real-time cross-sectional vessel wall imaging during endovascular procedures, improving stent sizing and deployment. Optical coherence tomography (OCT) offers 10-micron resolution for detailed plaque characterization. PET-CT with 18F-FDG identifies actively inflamed atherosclerotic plaques and is particularly useful for diagnosing large vessel vasculitis (Takayasu, giant cell arteritis). Antithrombotic therapy for vascular disease has evolved. The COMPASS trial (rivaroxaban 2.5 mg BID plus aspirin) established a new paradigm for patients with stable atherosclerotic vascular disease, demonstrating 24% relative risk reduction in MACE with acceptable bleeding risk. This dual-pathway inhibition is particularly beneficial for patients with polyvascular disease and PAD. For carotid artery disease, DAPT (aspirin plus clopidogrel) is used for 3 months after carotid stenting. SAPT with aspirin or clopidogrel is standard after CEA. The management of renal artery stenosis has shifted dramatically: the ASTRAL and CORAL trials showed no benefit of renal artery stenting over medical therapy for atherosclerotic renal artery stenosis, even in patients with significant stenosis and hypertension or renal dysfunction. Stenting is now reserved for FMD-related stenosis (where it remains effective) and select cases of atherosclerotic stenosis with recurrent flash pulmonary edema or refractory hypertension. Mesenteric ischemia presents as chronic mesenteric ischemia (CMI, postprandial abdominal pain, food fear, weight loss) or acute mesenteric ischemia (AMI, sudden severe abdominal pain out of proportion to examination, high mortality). CMI requires revascularization of at least one mesenteric vessel (typically the SMA). Endovascular stenting is first-line, with surgical bypass reserved for failures. AMI is a surgical emergency requiring embolectomy or bypass, with second-look laparotomy to assess bowel viability. Non-atherosclerotic vascular diseases require specific recognition. Fibromuscular dysplasia (FMD) is a non-inflammatory, non-atherosclerotic arterial disease most commonly affecting the renal arteries (60-75%) and internal carotid/vertebral arteries (25-30%) of young to middle-aged women. The classic "string-of-beads" appearance on angiography represents the medial fibroplasia subtype. Screening for multivessel FMD with head-to-pelvis CTA or MRA is recommended at diagnosis, as FMD frequently involves multiple arterial beds. Treatment includes antiplatelet therapy, blood pressure management, and angioplasty (without stenting) for symptomatic renal or carotid stenosis. Takayasu arteritis and giant cell arteritis (GCA) are large vessel vasculitides. Takayasu affects the aorta and its branches in young women (typically before age 40), causing stenoses, occlusions, and aneurysms. GCA affects the aorta and its branches in patients over 50, classically involving the temporal arteries. Both are treated with corticosteroids, with tocilizumab (anti-IL-6) now approved for GCA (GiACTA trial). Methotrexate is used as a steroid-sparing agent in both conditions.',
      keyTerms: [
        { term: 'Dual-pathway inhibition', definition: 'The combination of low-dose anticoagulation (rivaroxaban 2.5 mg BID) with antiplatelet therapy (aspirin) for enhanced atherosclerotic protection' },
        { term: 'Mesenteric ischemia', definition: 'Inadequate blood flow to the intestines causing abdominal pain, which can be chronic (postprandial) or acute (surgical emergency)' },
        { term: 'String-of-beads sign', definition: 'The classic angiographic appearance of fibromuscular dysplasia, representing alternating stenoses and dilations of the affected artery' },
        { term: 'Takayasu arteritis', definition: 'A large vessel vasculitis affecting the aorta and its branches in young women, causing stenoses, occlusions, and aneurysms' },
        { term: 'CORAL trial', definition: 'A landmark trial demonstrating no benefit of renal artery stenting over medical therapy for atherosclerotic renal artery stenosis' },
        { term: 'Tocilizumab', definition: 'An anti-IL-6 receptor antibody approved for giant cell arteritis, enabling corticosteroid sparing in this chronic vasculitis' }
      ],
      clinicalNotes: 'Three high-yield clinical reminders: (1) Do NOT stent atherosclerotic renal artery stenosis as a default (CORAL/ASTRAL). Medical therapy is first-line; stenting only for FMD, flash pulmonary edema, or refractory hypertension. (2) Acute mesenteric ischemia has the mantra "pain out of proportion to exam" with elevated lactate. Mortality exceeds 60% if not recognized early. CT angiography is diagnostic. (3) When diagnosing FMD in one artery, image the entire arterial tree (head to pelvis) as multivessel involvement is the rule rather than the exception.'
    },
    4: {
      level: 4,
      summary: 'Advanced vascular medicine encompasses complex aortic interventions, cerebrovascular hemodynamics, venous thromboembolic disease management, and comprehensive approaches to vasculitis, Raynaud phenomenon, and rare vascular conditions.',
      explanation: 'Advanced cerebrovascular disease management integrates hemodynamic assessment. Carotid disease evaluation has moved beyond simple stenosis measurement. Plaque characteristics matter: echolucent (lipid-rich) plaques, intraplaque hemorrhage (detected by MRI), plaque ulceration, and large juxtaluminal black area on ultrasound all predict stroke risk independent of stenosis degree. The ECST-2 trial is investigating optimal management of moderate asymptomatic carotid stenosis (50-69%) using plaque characteristics to guide CEA versus medical therapy. Hemodynamic assessment includes cerebral blood flow measurement using transcranial Doppler (TCD) to detect impaired cerebrovascular reserve (measured by CO2 reactivity or acetazolamide challenge). For carotid stenting, embolic protection devices (distal filter or proximal balloon occlusion) are standard. Transcarotid artery revascularization (TCAR) uses a direct carotid approach with flow reversal (directing embolic debris away from the brain) and has shown lower stroke rates than transfemoral CAS. Venous thromboembolic disease management involves risk stratification, appropriate anticoagulation duration, and consideration of advanced interventions. Acute DVT treatment is anticoagulation (DOAC preferred over warfarin per CHEST guidelines for non-cancer VTE). Catheter-directed thrombolysis for iliofemoral DVT (ATTRACT trial) did not reduce post-thrombotic syndrome overall but did reduce moderate-to-severe PTS in the iliofemoral DVT subgroup. For massive PE with hemodynamic instability, systemic thrombolysis (alteplase), surgical embolectomy, or catheter-directed therapy (ultrasound-assisted thrombolysis with EKOS or aspiration thrombectomy with FlowTriever/Inari) are options. The PERT (Pulmonary Embolism Response Team) model provides rapid multidisciplinary decision-making for submassive and massive PE. May-Thurner syndrome (iliac vein compression by the right common iliac artery) is an underrecognized cause of left lower extremity DVT, particularly in young women. Treatment involves iliac vein stenting. Popliteal vein entrapment syndrome and nutcracker syndrome (left renal vein compression) are other venous compression syndromes requiring recognition. Chronic venous disease management for advanced cases (CEAP C5-C6 with healed or active ulcers) involves compression therapy (multilayer bandaging, 30-40 mmHg stockings), wound care, and consideration of superficial venous ablation (endovenous laser or radiofrequency) if saphenous reflux contributes. The EVRA trial showed that early endovenous ablation combined with compression bandaging healed venous leg ulcers faster than compression alone. Advanced vasculitis management: medium-vessel vasculitis (polyarteritis nodosa) causes microaneurysms visible on mesenteric or renal angiography. Small vessel vasculitis (ANCA-associated: GPA, MPA, EGPA) can cause medium-vessel involvement. Treatment of large vessel vasculitis refractory to steroids and tocilizumab may require methotrexate, azathioprine, or biologics (ustekinumab, JAK inhibitors under investigation for Takayasu). Buerger disease (thromboangiitis obliterans) affects young male smokers, causing distal arterial occlusions with skip lesions and corkscrew collaterals. The only effective treatment is absolute smoking cessation; prostacyclin analogs (iloprost) may provide temporary symptomatic relief.',
      keyTerms: [
        { term: 'Transcarotid artery revascularization', definition: 'A carotid stenting approach using direct surgical carotid access with neuroprotective flow reversal to minimize stroke risk' },
        { term: 'May-Thurner syndrome', definition: 'Compression of the left common iliac vein by the right common iliac artery, predisposing to left lower extremity DVT' },
        { term: 'PERT model', definition: 'Pulmonary Embolism Response Team, a multidisciplinary model for rapid decision-making in submassive and massive pulmonary embolism' },
        { term: 'Buerger disease', definition: 'A non-atherosclerotic inflammatory arterial occlusive disease affecting young smokers, causing distal limb ischemia cured only by smoking cessation' },
        { term: 'Intraplaque hemorrhage', definition: 'Bleeding within an atherosclerotic carotid plaque detected by MRI, indicating a vulnerable plaque at high risk for embolization and stroke' }
      ],
      clinicalNotes: 'Three advanced clinical pearls: (1) TCAR is emerging as the preferred approach for carotid stenting when CEA risk is elevated, with stroke rates comparable to CEA in real-world registries. (2) May-Thurner syndrome should be suspected in any young patient (especially women) with left iliofemoral DVT; IVUS during venography is the gold standard for diagnosis and iliac vein stenting is curative. (3) For submassive PE (RV dilation without hemodynamic instability), the PERT model allows rapid multidisciplinary triage between anticoagulation alone, catheter-directed therapy, or surgical embolectomy based on patient-specific factors.'
    },
    5: {
      level: 5,
      summary: 'Expert vascular medicine integrates precision risk stratification using multi-omics biomarkers, endovascular innovation across all vascular beds, vascular cognitive impairment research, regenerative vascular therapies, and global health strategies for vascular disease prevention.',
      explanation: 'The frontier of vascular medicine is moving toward precision vascular care. Multi-omics approaches integrate genomics, transcriptomics, proteomics, and metabolomics for individual risk stratification. Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a novel cardiovascular risk factor: somatic mutations in hematopoietic stem cells (TET2, DNMT3A, ASXL1, JAK2) drive an inflammatory phenotype that accelerates atherosclerosis. Patients with CHIP have a 2-4 fold increased risk of cardiovascular events, potentially mediated through NLRP3 inflammasome activation. Whether targeting CHIP with anti-inflammatory therapy (canakinumab, colchicine) can reduce vascular events is under investigation. Mendelian randomization studies have identified causal risk factors for vascular disease beyond traditional targets: Lp(a) for aortic stenosis and PAD, IL-6 signaling for coronary disease and AAA, and complement system activation for AAA. These insights are driving novel therapeutic development. Vascular cognitive impairment (VCI) represents the intersection of vascular and neurological disease. Cerebral small vessel disease (white matter hyperintensities, lacunar infarcts, cerebral microbleeds on MRI) is driven by hypertension, diabetes, and atherosclerosis. VCI is the second most common cause of dementia after Alzheimer disease and frequently coexists with it. Aggressive vascular risk factor management (the SPRINT-MIND substudy showed that intensive BP lowering reduced mild cognitive impairment risk) is the only proven preventive strategy. Research into blood-brain barrier disruption, cerebral microvascular autoregulation, and neurovascular coupling is advancing understanding of cognitive consequences of vascular disease. Regenerative vascular therapies represent an exciting frontier: (1) Therapeutic angiogenesis using growth factors (VEGF, FGF) or gene therapy to stimulate new blood vessel growth in ischemic tissues has shown limited efficacy in clinical trials despite promising preclinical data. (2) Cell-based therapies including bone marrow mononuclear cells, mesenchymal stem cells, and endothelial progenitor cells are being studied for no-option CLI patients. (3) Tissue-engineered vascular grafts using decellularized scaffolds seeded with patient-derived cells may eliminate the need for autologous vein harvest. (4) 3D-bioprinted vascular constructs are in preclinical development. Endovascular innovation continues to push boundaries: robotic endovascular systems (CorPath GRX) enable remote catheter manipulation with sub-millimeter precision, potentially enabling telementored or even remote procedures in underserved areas. Drug-coated technologies continue to evolve beyond paclitaxel (sirolimus-coated balloons showing promise). Bioresorbable vascular scaffolds aim to provide temporary support before dissolving. Endovascular image fusion (overlaying pre-operative CT on real-time fluoroscopy) improves navigation and reduces contrast use. Global vascular disease prevention requires addressing the epidemiologic transition: as low- and middle-income countries develop, atherosclerotic vascular disease becomes the leading cause of death, replacing infectious disease. Population-level strategies (tobacco control, trans-fat bans, salt reduction, promotion of physical activity, and polypill strategies) are essential. The polypill concept (combining aspirin, statin, and antihypertensive in a single daily pill) has shown 30-40% cardiovascular risk reduction in the TIPS-3 and PolyIran trials, offering a scalable prevention strategy for resource-limited settings.',
      keyTerms: [
        { term: 'Clonal hematopoiesis of indeterminate potential', definition: 'Somatic mutations in blood stem cells that drive inflammation and accelerate atherosclerosis, a novel cardiovascular risk factor' },
        { term: 'Vascular cognitive impairment', definition: 'Cognitive decline caused by cerebrovascular disease, the second most common cause of dementia after Alzheimer disease' },
        { term: 'Therapeutic angiogenesis', definition: 'Strategies to stimulate new blood vessel growth in ischemic tissues using growth factors, gene therapy, or cell-based approaches' },
        { term: 'Robotic endovascular systems', definition: 'Robotic platforms enabling precise remote catheter manipulation during vascular interventions with sub-millimeter accuracy' },
        { term: 'Polypill strategy', definition: 'A fixed-dose combination of aspirin, statin, and antihypertensive in a single pill for scalable cardiovascular prevention in populations' },
        { term: 'Mendelian randomization', definition: 'A genetic epidemiology method using genetic variants as natural experiments to identify causal risk factors for vascular disease' }
      ],
      clinicalNotes: 'The expert vascular medicine perspective recognizes that: (1) Vascular disease is fundamentally a systemic inflammatory and metabolic disorder, not just a plumbing problem. Anti-inflammatory strategies (colchicine, PCSK9i, potentially CHIP-directed therapy) represent the next frontier beyond lipid lowering. (2) Cognitive preservation should be considered a vascular outcome alongside MI, stroke, and amputation prevention. (3) The global burden of vascular disease will increase dramatically in coming decades as developing nations undergo epidemiologic transition. Population-level prevention strategies (polypill, tobacco control, risk factor screening) are as important as individual patient management in reducing the global toll of vascular disease.'
    }
  },
  media: [],
  citations: [
    {
      id: 'visseren-2021',
      text: 'Visseren FLJ, Mach F, Smulders R, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.',
      url: 'https://doi.org/10.1093/eurheartj/ehab484'
    },
    {
      id: 'eikelboom-2017',
      text: 'Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS). N Engl J Med. 2017;377(14):1319-1330.',
      url: 'https://doi.org/10.1056/NEJMoa1709118'
    },
    {
      id: 'gornik-2019',
      text: 'Gornik HL, Persu A, Adlam D, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24(2):164-189.',
      url: 'https://doi.org/10.1177/1358863X18821816'
    }
  ],
  crossReferences: [
    { contentId: 'aorticaneurysm', relationship: 'child', description: 'Aortic aneurysm disease including AAA, TAA, screening, and surgical/endovascular repair' },
    { contentId: 'aorticdissection', relationship: 'child', description: 'Aortic dissection including classification, emergency management, and long-term surveillance' },
    { contentId: 'pad', relationship: 'child', description: 'Peripheral artery disease including claudication, CLTI, and revascularization strategies' }
  ],
  tags: {
    defined: ['vascular-disease', 'atherosclerosis', 'polyvascular', 'carotid-disease', 'venous-disease', 'vasculitis', 'fibromuscular-dysplasia', 'vascular-medicine'],
    source: ['ESC', 'AHA', 'ACC', 'SVS', 'ESVS']
  },
  createdAt: '2025-01-25',
  updatedAt: '2025-01-25',
  version: 2,
  status: 'published'
};
